Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Single centre ,Phase IV , interventional, The study includes :
200 patients, 100 Patients will have Topical r-Hirudin (Thrombexx) and 100 patients will have
placebo .
The patients will be randomized to the active product (arm 1) or to placebo (arm 2).
The study consists of 4 visits as the following :
- Visit 1 : on day 1 to check patient eligibility and also for randomization .
- Visit 2 : on day 4 to assess target parameters
- Visit 3 : on day 8 to assess target parameters
- Visit 4 : on day 16 to assess target parameters